In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Omega Therapeutics (OMGA – Research Report), ...

Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 21% growth forecast for ...

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.40 per share a year ago.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: November 1 at 5:14 p.m. EDT ...

Raymond James downgraded Omega Therapeutics (OMGA) to Market Perform from Outperform. Published first on TheFly – the ultimate source ...

Omega Therapeutics Inc. says its CEO, Mahesh Karande, has decided to leave the company for what it called "personal reasons,” ...

In a challenging year for biotech firms, Omega Therapeutics Inc. (OMGA) stock has reached a new 52-week low, touching down at $0.94. This latest price point reflects ...